Core Viewpoint - The article aims to provide informational content regarding investment opportunities and risks, emphasizing the importance of independent research and verification by readers [2][3]. Group 1: Company Analysis - The article does not provide specific details about any particular company or its financial performance, focusing instead on general investment advice [2][3]. Group 2: Industry Insights - There are no specific insights or analyses related to any industry mentioned in the article, as it primarily serves as a general informational piece [2][3].

Group 1: Biotechnology and Healthcare Companies Performance - Several biotechnology and healthcare companies experienced notable gains in after-hours trading due to clinical updates, financial results, and upcoming industry presentations [1] Group 2: ALX Oncology Holdings Inc. - ALX Oncology Holdings Inc. (ALXO) surged 10.17% to $1.30 after announcing positive data from a Phase 2 trial of its lead candidate, evorpacept, in combination with rituximab and lenalidomide for patients with indolent B-cell non-Hodgkin lymphoma [2] - The findings are scheduled to be presented on December 7, 2025, at the American Society of Hematology (ASH) Annual Meeting in Orlando, Florida [2] Group 3: Globus Medical, Inc. - Globus Medical, Inc. (GMED) climbed 9.34% to $99.00 following preliminary unaudited sales results, reporting fourth-quarter 2025 sales of approximately $823.2 million, a 25.2% increase year-over-year [3] - Full-year 2025 sales are expected to reach $2.936 billion, representing a 16.5% increase from the prior year [3] - The company set its 2026 revenue guidance between $3.18 billion and $3.22 billion, with projected non-GAAP earnings per share in the range of $4.30 to $4.40 [3] Group 4: Acrivon Therapeutics, Inc. - Acrivon Therapeutics, Inc. (ACRV) rose 6.44% to $3.14 after announcing plans to release clinical data updates for ACR-368 and ACR-2316 on January 8, 2026 [4] Group 5: Other Companies - AnaptysBio, Inc. (ANAB) advanced 1.75% to $46.00 after confirming that CEO Daniel Faga will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 [5] - Omeros Corp. (OMER) added 4.47% to $14.72 without any new corporate updates [6] - EUDA Health Holdings Limited (EUDA) increased 3.73% to $2.50 after amending its warrant agreement with Streeterville Capital, LLC [6] - TherapeuticsMD, Inc. (TXMD) rose 5.34% to $2.15 in after-hours trading, with no new announcements reported [6] - Pyxis Oncology, Inc. (PYXS) gained 4.93% to $1.49 without any fresh news [7]

Core Viewpoint - Globus Medical's preliminary fourth quarter 2025 financial results and fiscal 2026 guidance have positively influenced investor sentiment, leading to a significant increase in share price after hours trading [1][3]. Financial Performance - Globus Medical projects a 25.2% year-over-year sales growth for Q4 2025, estimating revenue of $823.2 million, which exceeds analysts' expectations of $778.3 million [3]. - For fiscal 2026, the company has provided revenue guidance of $3.18 billion to $3.22 billion and diluted adjusted earnings per share (EPS) guidance of $4.30 to $4.40, surpassing the analyst consensus of $4.12 [4]. Market Valuation - Despite the recent increase in share price, Globus Medical's stock is currently valued at 30.2 times trailing earnings, which is a discount compared to its five-year average P/E of 44.5, suggesting potential investment opportunities for those interested in healthcare stocks focused on orthopedic and spinal care [5][6].

Financial Results - Globus Medical, Inc. reported preliminary unaudited net sales results for the fiscal year ended December 31, 2025[5] - The company provided preliminary guidance for certain financial measures for the fiscal year ending December 31, 2026[5] Press Release - The press release regarding these results was issued on January 7, 2026[5]

Industry Overview - The MedTech sector is navigating a global economy characterized by slowing growth, moderating inflation, and heightened geopolitical uncertainty, impacting healthcare spending and capital allocation decisions [1][2] - Despite challenges such as higher input costs and labor shortages, demand for advanced medical technologies remains steady due to the sector's essential nature and long-term innovation cycle [1][2] Economic Outlook - The IMF forecasts gradual deceleration of global growth through 2026, with advanced economies growing slower than emerging markets, while global inflation is expected to ease unevenly across regions [2] - Slower economic growth may constrain healthcare budgets, but moderating inflation and improved financial conditions could alleviate cost pressures and stabilize procurement trends [2][3] Future Projections - By 2026, the MedTech sector is anticipated to benefit from a more stable macro environment if inflation continues to decline and financing conditions remain favorable [3] - Demand is expected to favor technologies that enhance efficiency, outpatient care, and automation, positioning strong MedTech companies for better performance in a slower-growth economy [3] Investment Considerations - Investors may need to reassess MedTech companies that have seen significant gains but could face challenges in 2026 due to selective hospital spending and increased competition [4][9] - Companies like Globus Medical, TransMedics, and Hims & Hers have experienced strong growth driven by innovation, but sustaining this momentum may be difficult as macro conditions normalize [4][8][9] Company Highlights - **Globus Medical (GMED)**: Reported solid growth in Q3 2025, with a projected EPS and revenue increase of 3.9% and 7.9% respectively for 2026. The stock gained 3.8% over the past year [10][11] - **TransMedics (TMDX)**: Announced strong Q3 2025 results and a strategic collaboration for organ transportation. Expected EPS and revenue growth of 2.4% and 20.4% respectively for 2026. The stock surged 101.4% over the past year [12][14] - **Hims & Hers (HIMS)**: Reported strong Q3 2025 results with growth in subscribers and revenue. Projected EPS and revenue growth of 22.3% and 17.6% respectively for 2026. The stock increased by 32.6% over the past year [15][18]

Market Overview - U.S. stock markets have continued to rise in 2025, with the Dow and S&P 500 gaining 0.3% and 0.1% in November, while the Nasdaq Composite fell by 1.5% [1][2] - Year-to-date performance shows the Dow, S&P 500, and Nasdaq Composite up by 12.6%, 16.7%, and 21.2%, respectively, with expectations of continued growth in December due to a potential interest rate cut by the Fed [3] Investment Opportunities - Recommended stocks for December include Expedia Group Inc. (EXPE), The Allstate Corp. (ALL), Dillard's Inc. (DDS), Kinross Gold Corp. (KGC), and Globus Medical Inc. (GMED), all carrying a Zacks Rank 1 (Strong Buy) and a Zacks Momentum Score of A [4][9] Company Highlights Expedia Group Inc. (EXPE) - Benefits from a strong platform model that enhances customer insights and revenue growth, with an expected revenue growth rate of 6.3% and earnings growth rate of 20.8% for next year [7][8] - Strong liquidity, share buybacks, and dividends highlight financial resilience [8] The Allstate Corp. (ALL) - Consistent growth in premiums with a 7.6% year-over-year increase in net premiums earned in the first nine months of 2025 [10][11] - Expected revenue growth rate of 5.7% and a decline in earnings by 14.5% for next year, with share repurchases totaling $805 million in the first nine months of 2025 [12][11] Dillard's Inc. (DDS) - Capturing growth in both brick-and-mortar and e-commerce, with a 1% year-over-year increase in retail sales [13][14] - Expected revenue growth rate of 0.8% and a decline in earnings by 8.2% for next year [16] Kinross Gold Corp. (KGC) - Strong production profile with a focus on organic growth through projects like the Tasiast mine, which has boosted production capacity [17][18] - Expected revenue growth rate of 6.3% and earnings growth rate of 32% for next year [19] Globus Medical Inc. (GMED) - Strengthened position in the musculoskeletal space through acquisitions, with a focus on expanding product offerings [20][21] - Expected revenue growth rate of 7.2% and earnings growth rate of 11.3% for next year [22]

Core Insights - The U.S. equity markets are currently experiencing volatility due to high valuations, sluggish economic signals, and uncertainty regarding the Federal Reserve's future actions, particularly affecting growth and AI-linked stocks [1] Group 1: Stock Selection Strategy - Retail investors face challenges in stock selection amidst market volatility, making traditional stock-picking methods more relevant [2] - Sales growth is emphasized as a more reliable metric for evaluating stocks compared to earnings growth, as it reflects underlying demand and business model durability [3][10] - Sustained sales growth leads to predictable cash flows, allowing companies to reinvest and maintain stability without excessive borrowing [5] Group 2: Screening Parameters for Stocks - Selected stocks should have a 5-Year Historical Sales Growth (%) greater than the industry average and Cash Flow exceeding $500 million [6] - Additional criteria include a Price-to-Sales (P/S) Ratio lower than the industry average, indicating better value for revenue [7] - Positive revisions in sales estimates compared to the industry can trigger stock price increases [7] Group 3: Key Metrics for Evaluation - An operating margin greater than 5% over the last five years indicates effective cost control and sales growth outpacing costs [8] - A Return on Equity (ROE) greater than 5% ensures that sales growth translates into profits, indicating wise spending and profitability [9] - Stocks with a Zacks Rank of 1 (Strong Buy) or 2 (Buy) are expected to outperform in various market conditions [9] Group 4: Recommended Stocks - Take-Two Interactive (TTWO) is projected to have a sales growth rate of 14.8% for fiscal 2026 and holds a Zacks Rank of 1 [11] - Globus Medical (GMED) anticipates a sales growth rate of 14.5% for 2025, also with a Zacks Rank of 1 [12] - Rockwell Automation (ROK) expects a sales increase of 5.8% in fiscal 2026 and has a Zacks Rank of 2 [13] - Canadian Natural Resources (CNQ) forecasts a sales growth of 5.7% for 2025, currently holding a Zacks Rank of 1 [14] - VICI Properties anticipates a sales growth of 4.1% in 2025 and has a Zacks Rank of 2 [15]

Group 1 - Globus Medical (GMED) has reached the buy point of a long, deep cup-with-handle base in above average volume, indicating strong market interest [1] - The stock is on track for four consecutive weeks of gains, reflecting positive momentum in its performance [1] - Globus Medical was added to the IBD Leaderboard Leaders list, highlighting its status as a top-performing stock [1] Group 2 - Medtronic's stock has seen a 36% surge following blowout quarterly earnings, indicating strong performance in the medical products sector [4] - Globus Medical's composite rating has climbed to 96, showcasing its competitive position in the market [4] - The relative strength rating of Globus Medical has improved to 84, suggesting enhanced technical strength [4]

Core Viewpoint - Globus Medical, Inc. (GMED) is showing potential as a strong stock pick due to a recent "golden cross" event, indicating a bullish trend reversal [1][2]. Technical Indicators - A "golden cross" occurs when a stock's short-term moving average (50-day) crosses above its long-term moving average (200-day), suggesting a bullish breakout is likely [2]. - The golden cross pattern consists of three stages: a downtrend followed by a crossover of moving averages, and finally an upward price movement [3]. Performance Metrics - Over the past four weeks, GMED has experienced a significant price increase of 38.1% [4]. - GMED currently holds a 1 (Strong Buy) rating on the Zacks Rank, indicating strong potential for further price appreciation [4]. Earnings Outlook - The earnings outlook for GMED is positive, with four upward revisions in earnings estimates over the past 60 days, and no downward revisions [4]. - The Zacks Consensus Estimate for GMED has also increased, reinforcing the bullish sentiment around the stock [4]. Investment Consideration - Given the technical indicators and positive earnings revisions, GMED should be considered for inclusion on investors' watchlists [6].

Market Overview - U.S. stocks have shown resilience, maintaining a strong upswing despite volatility, with major indexes near record levels supported by robust corporate earnings and investor appetite [1][2] - The end of the government shutdown has alleviated concerns, allowing for a more optimistic outlook on gradual policy easing from the Federal Reserve [2] Investment Strategy - A relative price strength strategy is recommended, focusing on stocks that outperform the market even during pauses, which helps investors align with market leadership [3][4] - Stocks that exceed their industry or benchmark performance should be prioritized for inclusion in investment portfolios, as they are more likely to yield significant returns [5] Stock Screening Criteria - Stocks should demonstrate positive relative price changes over 1, 4, and 12 weeks, outperforming the S&P 500 [8] - The screening highlights five stocks with strong relative price strength amid market gains, including Par Pacific Holdings, AngloGold Ashanti, Globus Medical, Allient Inc., and Sandisk Corporation [8] Company Highlights - **Par Pacific Holdings (PARR)**: Market cap of $2.2 billion, with a 146.2% share gain over the past year and a 112.3% increase in 2025 earnings estimates [11][8] - **AngloGold Ashanti (AU)**: Market cap over $33 billion, with a 220% share gain in the past year and a 162.4% year-over-year growth in 2025 earnings estimates [12][11] - **Globus Medical (GMED)**: Expected EPS growth rate of 14.3%, with a 3.2% share increase in a year and a positive revision in earnings estimates [13][14] - **Allient Inc. (ALNT)**: Market cap nearly $900 million, with a 117.7% share gain in a year and a 5.2% increase in 2025 earnings estimates [15][16] - **Sandisk Corporation (SNDK)**: Market cap of $37.3 billion, with a 422.9% share gain in a year and a 308% growth in fiscal 2026 earnings estimates [17][18]